nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—POMC—autonomic nervous system—Gilles de la Tourette syndrome	0.282	0.307	CbGeAlD
Loperamide—CALM1—autonomic nervous system—Gilles de la Tourette syndrome	0.0766	0.0835	CbGeAlD
Loperamide—POMC—midbrain—Gilles de la Tourette syndrome	0.0433	0.0473	CbGeAlD
Loperamide—POMC—nervous system—Gilles de la Tourette syndrome	0.0356	0.0389	CbGeAlD
Loperamide—POMC—central nervous system—Gilles de la Tourette syndrome	0.0343	0.0374	CbGeAlD
Loperamide—CACNA1A—nervous system—Gilles de la Tourette syndrome	0.034	0.0371	CbGeAlD
Loperamide—CACNA1A—central nervous system—Gilles de la Tourette syndrome	0.0328	0.0357	CbGeAlD
Loperamide—POMC—brain—Gilles de la Tourette syndrome	0.0272	0.0297	CbGeAlD
Loperamide—CACNA1A—brain—Gilles de la Tourette syndrome	0.026	0.0284	CbGeAlD
Loperamide—OPRD1—nervous system—Gilles de la Tourette syndrome	0.0197	0.0214	CbGeAlD
Loperamide—OPRD1—central nervous system—Gilles de la Tourette syndrome	0.0189	0.0206	CbGeAlD
Loperamide—OPRK1—nervous system—Gilles de la Tourette syndrome	0.0189	0.0206	CbGeAlD
Loperamide—OPRK1—central nervous system—Gilles de la Tourette syndrome	0.0182	0.0198	CbGeAlD
Loperamide—OPRM1—midbrain—Gilles de la Tourette syndrome	0.0163	0.0178	CbGeAlD
Loperamide—CALM3—midbrain—Gilles de la Tourette syndrome	0.0151	0.0164	CbGeAlD
Loperamide—OPRD1—brain—Gilles de la Tourette syndrome	0.015	0.0164	CbGeAlD
Loperamide—OPRK1—brain—Gilles de la Tourette syndrome	0.0144	0.0157	CbGeAlD
Loperamide—OPRM1—nervous system—Gilles de la Tourette syndrome	0.0134	0.0146	CbGeAlD
Loperamide—OPRM1—central nervous system—Gilles de la Tourette syndrome	0.0129	0.0141	CbGeAlD
Loperamide—CALM2—midbrain—Gilles de la Tourette syndrome	0.0118	0.0129	CbGeAlD
Loperamide—Haloperidol—DRD4—Gilles de la Tourette syndrome	0.0118	0.342	CrCbGaD
Loperamide—CALM1—midbrain—Gilles de la Tourette syndrome	0.0118	0.0128	CbGeAlD
Loperamide—OPRM1—brain—Gilles de la Tourette syndrome	0.0103	0.0112	CbGeAlD
Loperamide—Haloperidol—DRD3—Gilles de la Tourette syndrome	0.0102	0.295	CrCbGaD
Loperamide—CALM2—nervous system—Gilles de la Tourette syndrome	0.00973	0.0106	CbGeAlD
Loperamide—CALM1—nervous system—Gilles de la Tourette syndrome	0.00969	0.0106	CbGeAlD
Loperamide—CALM3—brain—Gilles de la Tourette syndrome	0.00947	0.0103	CbGeAlD
Loperamide—CALM2—central nervous system—Gilles de la Tourette syndrome	0.00937	0.0102	CbGeAlD
Loperamide—CALM1—central nervous system—Gilles de la Tourette syndrome	0.00933	0.0102	CbGeAlD
Loperamide—CALM2—brain—Gilles de la Tourette syndrome	0.00744	0.00811	CbGeAlD
Loperamide—CALM1—brain—Gilles de la Tourette syndrome	0.00741	0.00807	CbGeAlD
Loperamide—CYP2B6—nervous system—Gilles de la Tourette syndrome	0.00724	0.00789	CbGeAlD
Loperamide—Haloperidol—DRD2—Gilles de la Tourette syndrome	0.00704	0.204	CrCbGaD
Loperamide—CYP2B6—central nervous system—Gilles de la Tourette syndrome	0.00697	0.0076	CbGeAlD
Loperamide—CYP2C8—brain—Gilles de la Tourette syndrome	0.00617	0.00672	CbGeAlD
Loperamide—CYP2B6—brain—Gilles de la Tourette syndrome	0.00553	0.00603	CbGeAlD
Loperamide—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00546	0.00596	CbGeAlD
Loperamide—Haloperidol—HTR2A—Gilles de la Tourette syndrome	0.00544	0.158	CrCbGaD
Loperamide—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00538	0.00586	CbGeAlD
Loperamide—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00526	0.00574	CbGeAlD
Loperamide—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00518	0.00564	CbGeAlD
Loperamide—ABCB1—midbrain—Gilles de la Tourette syndrome	0.0047	0.00513	CbGeAlD
Loperamide—CYP2D6—brain—Gilles de la Tourette syndrome	0.00411	0.00448	CbGeAlD
Loperamide—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00387	0.00422	CbGeAlD
Loperamide—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00372	0.00406	CbGeAlD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00297	0.0613	CbGpPWpGaD
Loperamide—ABCB1—brain—Gilles de la Tourette syndrome	0.00296	0.00322	CbGeAlD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0026	0.0538	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0022	0.0455	CbGpPWpGaD
Loperamide—POMC—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00133	0.0274	CbGpPWpGaD
Loperamide—POMC—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00129	0.0266	CbGpPWpGaD
Loperamide—CACNA1A—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0012	0.0248	CbGpPWpGaD
Loperamide—POMC—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.0012	0.0248	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00106	0.0218	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00102	0.0212	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000954	0.0197	CbGpPWpGaD
Loperamide—CACNA1A—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00092	0.019	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000804	0.0166	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00078	0.0161	CbGpPWpGaD
Loperamide—POMC—Metabolism—HDC—Gilles de la Tourette syndrome	0.000771	0.0159	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000727	0.015	CbGpPWpGaD
Loperamide—POMC—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000668	0.0138	CbGpPWpGaD
Loperamide—CACNA1A—Metabolism—HDC—Gilles de la Tourette syndrome	0.000666	0.0138	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000527	0.0109	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000511	0.0106	CbGpPWpGaD
Loperamide—POMC—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000509	0.0105	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000489	0.0101	CbGpPWpGaD
Loperamide—OPRD1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000476	0.00984	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000475	0.0098	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000462	0.00954	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000454	0.00938	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000448	0.00926	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000442	0.00913	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000441	0.00911	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000429	0.00885	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000419	0.00865	CbGpPWpGaD
Loperamide—OPRK1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000418	0.00863	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000416	0.00859	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000412	0.00852	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000411	0.00848	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000407	0.0084	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.0004	0.00827	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00039	0.00806	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000388	0.00801	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000379	0.00783	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000379	0.00782	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000373	0.0077	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000367	0.00758	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000362	0.00748	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000356	0.00736	CbGpPWpGaD
Loperamide—OPRM1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000353	0.00729	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000352	0.00726	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000332	0.00686	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000328	0.00677	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000319	0.00659	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00031	0.00641	CbGpPWpGaD
Loperamide—OPRD1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00031	0.00639	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00031	0.00639	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000301	0.00622	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000288	0.00596	CbGpPWpGaD
Loperamide—POMC—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000288	0.00594	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000281	0.0058	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00028	0.00578	CbGpPWpGaD
Loperamide—OPRK1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000271	0.00561	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000271	0.00561	CbGpPWpGaD
Loperamide—OPRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000265	0.00548	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000261	0.0054	CbGpPWpGaD
Loperamide—CALM3—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000253	0.00523	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000253	0.00522	CbGpPWpGaD
Loperamide—CALM2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000245	0.00505	CbGpPWpGaD
Loperamide—CALM1—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000245	0.00505	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000244	0.00503	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000236	0.00488	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000236	0.00488	CbGpPWpGaD
Loperamide—OPRK1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000233	0.0048	CbGpPWpGaD
Loperamide—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000229	0.00474	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000229	0.00474	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00022	0.00455	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000214	0.00441	CbGpPWpGaD
Loperamide—OPRD1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000202	0.00417	CbGpPWpGaD
Loperamide—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000197	0.00406	CbGpPWpGaD
Loperamide—CALM3—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000194	0.004	CbGpPWpGaD
Loperamide—CALM1—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000188	0.00387	CbGpPWpGaD
Loperamide—CALM2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000188	0.00387	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00018	0.00372	CbGpPWpGaD
Loperamide—OPRK1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000177	0.00366	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000175	0.00361	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000164	0.00338	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000163	0.00337	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000159	0.00328	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000158	0.00326	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000154	0.00319	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000153	0.00317	CbGpPWpGaD
Loperamide—OPRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00015	0.00309	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000148	0.00306	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000144	0.00298	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000143	0.00296	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000143	0.00295	CbGpPWpGaD
Loperamide—CALM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00014	0.0029	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000139	0.00288	CbGpPWpGaD
Loperamide—CALM1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000136	0.0028	CbGpPWpGaD
Loperamide—CALM2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000136	0.0028	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000134	0.00276	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00013	0.00268	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00013	0.00268	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	0.000122	0.00252	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000121	0.00251	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000121	0.00249	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000118	0.00243	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000114	0.00236	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00011	0.00227	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000106	0.0022	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000104	0.00214	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.0001	0.00207	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0001	0.00207	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.67e-05	0.002	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.39e-05	0.00194	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	9.09e-05	0.00188	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	8.74e-05	0.00181	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.48e-05	0.00175	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	8.46e-05	0.00175	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.23e-05	0.0017	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	7.9e-05	0.00163	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	7.68e-05	0.00159	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	7.67e-05	0.00158	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.51e-05	0.00155	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.29e-05	0.00151	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.26e-05	0.0015	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	7.26e-05	0.0015	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.16e-05	0.00148	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.05e-05	0.00146	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.05e-05	0.00146	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.96e-05	0.00144	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.79e-05	0.0014	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.57e-05	0.00136	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.57e-05	0.00136	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	6.55e-05	0.00135	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.48e-05	0.00134	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.12e-05	0.00126	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.37e-05	0.00111	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.76e-05	0.000982	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.6e-05	0.00095	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.6e-05	0.00095	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.54e-05	0.000937	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.43e-05	0.000916	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.31e-05	0.000889	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.29e-05	0.000886	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.29e-05	0.000886	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.16e-05	0.00086	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.16e-05	0.00086	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.01e-05	0.000828	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.88e-05	0.000801	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.88e-05	0.000801	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.81e-05	0.00058	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.72e-05	0.000561	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.72e-05	0.000561	CbGpPWpGaD
